Certified by Founder Lodge
AvenCell
United States - Cambridge, Massachusetts
START UP
1 Disclosed Funding Rounds $112,000,000
0 Participating Investments
-
Founded date
2021
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| October, 22 ,2024 | Series B | $112,000,000 |
Eight Roads
Novo Holdings
NYBC Ventures
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
Iridius | $8,600,000 | (Apr 28, 2026)
Fathom Therapeutics | $47,000,000 | (Apr 28, 2026)
Decade Energy | $25,763,540 | (Apr 28, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Audion | $15,000,000 | (Apr 28, 2026)
